Unlocking the Potential of KCNA2: A Potassium Channel Subfamily A Member 2 (ISO Form A) Drug Target and Biomarker

Target Name: KCNA2

NCBI ID: G3737

KCNA2

Unlocking the Potential of KCNA2: A Potassium Channel Subfamily A Member 2 (ISO Form A) Drug Target and Biomarker

Introduction

KCNA2, a member of the Potassium voltage-gated channel subfamily A (KCNA), is an essential protein that plays a crucial role in various physiological processes in the nervous system, including muscle contractions and neurotransmitter release. The KCNA2 channel is involved in the regulation of intracellular potassium levels, which is known to play a pivotal role in neurotransmitter release and signaling. Thus, modulating KCNA2 function could provide new insights into the pathophysiology of neurological disorders and potential therapeutic interventions.

Drug Target Potential

KCNA2 has been identified as a potential drug target due to its unique function in the regulation of intracellular potassium levels. Several studies have shown that modulating KCNA2 activity can lead to therapeutic effects in various neurological disorders, including epilepsy, Alzheimer's disease, and Parkinson's disease.

In epilepsy, KCNA2 has been shown to play a negative role in the regulation of neuronal excitability, which may contribute to the pathophysiology of epilepsy. Therefore, inhibiting KCNA2 function has been shown to be a potential therapeutic approach for the treatment of epilepsy.

In Alzheimer's disease, KCNA2 has been shown to be involved in the regulation of neurotransmitter release and the maintenance of neuronal excitability. Therefore, modulating KCNA2 function may be a promising approach for the development of new therapeutic interventions for Alzheimer's disease.

In Parkinson's disease, KCNA2 has been implicated in the regulation of the release of dopamine, a key neurotransmitter involved in motor function. Therefore, modulating KCNA2 function may be a potential therapeutic approach for the treatment of Parkinson's disease.

Biomarker Potential

KCNA2 has also been identified as a potential biomarker for various neurological disorders, including epilepsy, Alzheimer's disease, and Parkinson's disease. The levels of KCNA2 have been shown to be affected in these disorders, which may provide a potential target for diagnostic biomarkers.

In epilepsy, studies have shown that the levels of KCNA2 are altered in the temporal cortical regions of patients with certain types of epilepsy. Therefore, measuring the levels of KCNA2 may be a potential biomarker for the diagnosis of epilepsy.

In Alzheimer's disease, studies have shown that the levels of KCNA2 are altered in the prefrontal cortical regions of patients with Alzheimer's disease. Therefore, measuring the levels of KCNA2 may be a potential biomarker for the diagnosis of Alzheimer's disease.

In Parkinson's disease, studies have shown that the levels of KCNA2 are altered in the dopamine-producing neurons of patients with Parkinson's disease. Therefore, measuring the levels of KCNA2 may be a potential biomarker for the diagnosis of Parkinson's disease.

Conclusion

In conclusion, KCNA2 is a member of the Potassium voltage-gated channel subfamily A that plays a crucial role in various physiological processes in the nervous system. The modulation of KCNA2 function has been shown to be involved in the regulation of intracellular potassium levels, which is implicated in the pathophysiology of various neurological disorders. Thus, modulating KCNA2 function may provide new insights into the development of therapeutic interventions for these disorders. Additionally, KCNA2 has also been identified as a potential biomarker for the diagnosis of several neurological disorders, including epilepsy , Alzheimer's disease, and Parkinson's disease. Therefore, measuring the levels of KCNA2 may be a promising approach for the development of new diagnostic biomarkers for these disorders.

Protein Name: Potassium Voltage-gated Channel Subfamily A Member 2

Functions: Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain and the central nervous system, but also in the cardiovascular system. Prevents aberrant action potential firing and regulates neuronal output. Forms tetrameric potassium-selective channels through which potassium ions pass in accordance with their electrochemical gradient. The channel alternates between opened and closed conformations in response to the voltage difference across the membrane (PubMed:19912772, PubMed:8495559, PubMed:11211111, PubMed:23769686). Can form functional homotetrameric channels and heterotetrameric channels that contain variable proportions of KCNA1, KCNA2, KCNA4, KCNA5, KCNA6, KCNA7, and possibly other family members as well; channel properties depend on the type of alpha subunits that are part of the channel (PubMed:8495559, PubMed:20220134). Channel properties are modulated by cytoplasmic beta subunits that regulate the subcellular location of the alpha subunits and promote rapid inactivation of delayed rectifier potassium channels. In vivo, membranes probably contain a mixture of heteromeric potassium channel complexes, making it difficult to assign currents observed in intact tissues to any particular potassium channel family member. Homotetrameric KCNA2 forms a delayed-rectifier potassium channel that opens in response to membrane depolarization, followed by slow spontaneous channel closure (PubMed:19912772, PubMed:23769686). In contrast, a heteromultimer formed by KCNA2 and KCNA4 shows rapid inactivation (PubMed:8495559). Regulates neuronal excitability and plays a role as pacemaker in the regulation of neuronal action potentials (By similarity). KCNA2-containing channels play a presynaptic role and prevent hyperexcitability and aberrant action potential firing (By similarity). Response to toxins that are selective for KCNA2-containing potassium channels suggests that in Purkinje cells, dendritic subthreshold KCNA2-containing potassium channels prevent random spontaneous calcium spikes, suppressing dendritic hyperexcitability without hindering the generation of somatic action potentials, and thereby play an important role in motor coordination (By similarity). Plays a role in the induction of long-term potentiation of neuron excitability in the CA3 layer of the hippocampus (By similarity). May function as down-stream effector for G protein-coupled receptors and inhibit GABAergic inputs to basolateral amygdala neurons (By similarity). May contribute to the regulation of neurotransmitter release, such as gamma-aminobutyric acid (GABA) (By similarity). Contributes to the regulation of the axonal release of the neurotransmitter dopamine (By similarity). Reduced KCNA2 expression plays a role in the perception of neuropathic pain after peripheral nerve injury, but not acute pain (By similarity). Plays a role in the regulation of the time spent in non-rapid eye movement (NREM) sleep (By similarity)

The "KCNA2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KCNA2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets